The invention relates to a specialized subpopulation of natural killer cells that have enhanced effector functions and the potential to kill malignant tumor cells or infected cells when the natural killer cells are exposed to an antibody bound to the tumor cells or the infected cells.

The invention relates to a specialized subpopulation of natural killer cells that have enhanced effector functions and the potential to kill malignant tumor cells or infected cells when the natural killer cells are exposed to an antibody bound to the tumor cells or the infected cells.

The present invention relates generally to immunization and immunotherapy for the treatment or prevention of HIV. In particular, the methods include in vivo and/or ex vivo enrichment of HIV-specific CD4+ T cells.

The present invention relates generally to immunization and immunotherapy for the treatment or prevention of HIV. In particular, the methods include in vivo and/or ex vivo enrichment of HIV-specific CD4+ T cells.

Provided herein are compositions and methods related to the treatment of a CMV infection and/or cancer in a subject.

Provided herein are compositions and methods related to the treatment of a CMV infection and/or cancer in a subject.

Chimeric antigen receptors (CAR) targeted to glycoprotein D (gD) and immune cells (e.g., T cells and NK cells) expressing such CAR are described. Nucleic acids encoding a gD-CAR and immune cells (e.g., T cells and NK cells) comprising such nucleic acids are also described. Methods of making and using (e.g., treating a cancer and treating a Herpes Simplex Virus infection) such immune cells with or without combining treatment with an oncolytic Herpes Simplex Virus are also disclosed.

Chimeric antigen receptors (CAR) targeted to glycoprotein D (gD) and immune cells (e.g., T cells and NK cells) expressing such CAR are described. Nucleic acids encoding a gD-CAR and immune cells (e.g., T cells and NK cells) comprising such nucleic acids are also described. Methods of making and using (e.g., treating a cancer and treating a Herpes Simplex Virus infection) such immune cells with or without combining treatment with an oncolytic Herpes Simplex Virus are also disclosed.

The invention pertains to methods for using chimeric polypeptides of the formula:

B-X

wherein B represents the B fragment of Shiga toxin or a functional equivalent thereof, and X represents one or more polypeptides of therapeutic significance. Compositions for therapeutic use comprising the polypeptide B-X are also included.

According to the present invention, there are provided a method for producing a human T cell, which comprises the steps of inducing an iPS cell from a human T cell, and differentiating the iPS cell into a T cell; a pharmaceutical composition comprising the T cell produced by the method; and a method for cell-based immunotherapy using the method.